 
 
 
Fatty acid supplements alter biological signatures in children with 
Autism Spectrum Disorder  
 
 
 
Principal Investigator:   Sarah A. Keim , PhD  
Co-Principal Investigator: Lynette K. Rogers, PhD  
 
 
CONFIDENTIAL  
 
 
Version 5 
Protocol Version 1 was submitted to the FDA in November 2016  and at initial grant submission . 
Protocol Version 2 was submitted to NIH Nov 2017. No participants were enrolled under 
Protocol Version 1 ,2,3,4. 
 
 
 
22 May  2018 
 
 
 
               Fatty acid supplements alter biological signat ures in ASD                                                                                     Updated:  
CONFIDENTIAL                                                                                                                                                                22 May  2018 
 
  ii 
 STATEMENT OF COMPLIA NCE  
The study will be carried out in accordance  with Good Clinical Practice (GC P) as required by the 
following : 
 
 United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45  CFR 
Part 46; 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312 ) 
 ICH E6; 62 Federal Register 25691 (1 997)  
 NIH Clinical Terms of Award  
 
All key personnel (all individuals responsible for the design and conduct of this study) have 
completed Human Subjects Protection Training.  
 
               Fatty acid supplements alter biological signat ures in ASD                                                                                     Updated:  
CONFIDENTIAL                                                                                                                                                                22 May  2018 
 
  iii 
 SIGNATURE PAGE  
The signature below constitutes the approval of this protocol an d the attachments, and provides the 
necessary assurances that this trial will be conducted according to all stipulations of the protocol, 
including all statements regarding confidentiality, and according to local legal and regulatory 
requirements and appli cable US federal regulations and ICH guidelines.  
 
Site Investigator:*  
 
Signed:   Date:   
 Name  
Title 
   
*The protocol should be signed by the local investigator who is responsible for the study 
implementation at his/her specific site; i.e., if Investigati onal New Drug study, the individual who 
signs the Form FDA 1572.  
               Fatty acid supplements alter biological signat ures in ASD                                                                                     Updated:  
CONFIDENTIAL                                                                                                                                                                22 May  2018 
 
  iv 
 TABLE OF CONTENTS  
 Page  
Statement of Compliance  ................................ ................................ ................................ ................  ii 
Signature Page  ................................ ................................ ................................ ...............................  iii 
Table of Contents  ................................ ................................ ................................ ............................  iv 
Protocol Summary  ................................ ................................ ................................ .........................  vii 
1 Key Roles  ................................ ................................ ................................ ...............................  8 
2 Background Information and Scientific Rationale  ................................ ................................ . 9 
2.1 Introduction  ................................ ................................ ................................ ................  9 
2.2 Biological Pathways and Mechanisms  ................................ ................................ .... 10 
2.3 Advantages of Fatty Acid Combination Therapies  ................................ ..................  10 
2.4 Inflammation in Patients with ASD  ................................ ................................ ..........  11 
2.5 Evidence for the Need for Early Intervention and Tailored Dosing  .........................  11 
2.6 Consideration of Comorbidities Common in ASD  ................................ ...................  11 
3 Study AIMS  ................................ ................................ ................................ ..........................  13 
3.1 Study Outcome Measures  ................................ ................................ .......................  13 
4 Study Design  ................................ ................................ ................................ ........................  14 
4.1 Study Participants  ................................ ................................ ................................ .... 14 
5 Study Enrollment, TREATMENT ASSIGNMENT, and Withdraw  ................................ ....... 15 
5.1 Enrollment  ................................ ................................ ................................ ................  15 
5.1.1  Medical Record Data  ................................ ................................ ...................  15 
5.1.2  Recruitment Mailing  ................................ ................................ .....................  15 
5.1.3  Recruitment Contact  ................................ ................................ ....................  15 
5.1.4  Treatment Assignment  ................................ ................................ .................  16 
5.1.5 Randomization and Masking Procedures  ................................ ...................  16 
5.1.6  Emergency Unblinding  ................................ ................................ .................  17 
5.1.7  Withdraw  ................................ ................................ ................................ ...... 17 
5.1.8  Handling of Withdrawals  ................................ ................................ ..............  17 
5.1.9  Termination of Study  ................................ ................................ ....................  17 
6 Study Procedures and Schedule of Eve nts ................................ ................................ .........  18 
6.1 Visit 1 (Day 0)  ................................ ................................ ................................ ..........  18 
6.2 Visit 2 (Day 25 phone contact)  ................................ ................................ ................  19 
6.3 Visit 3 (Day 45)  ................................ ................................ ................................ ........  19 
6.4 Visit 4 (Day 90)  ................................ ................................ ................................ ........  20 
6.5 Additional Routine Communication (throughout participation)  ...............................  20 
6.6 Rationale for Data Collection  ................................ ................................ ...................  20 
7 Laboratory evaluations  ................................ ................................ ................................ ........  21 
7.1 Spec imen Preparation, Handling, and Shipping  ................................ .....................  21 
7.2 Biohazards  ................................ ................................ ................................ ...............  21 
8 Investigational Product  ................................ ................................ ................................ ........  22 
8.1 Acquisition  ................................ ................................ ................................ ................  22 
8.2 Formulation, Packaging, and Labeling  ................................ ................................ .... 22 
8.3 Dispension  ................................ ................................ ................................ ...............  23 
8.4 Product Storage and Stability  ................................ ................................ ..................  23 
8.5 Dosage, Preparation and Administration ................................ ................................ . 23 
               Fatty acid supplements alter biological signat ures in ASD                                                                                     Updated:  
CONFIDENTIAL                                                                                                                                                                22 May  2018 
 
  v 
 8.6 Modification of Investigational Product  ................................ ................................ .... 23 
8.7 Accountability Procedures for the Investigational Product  ................................ ...... 23 
8.8 Assessment of  Subject Compliance with the Investigational Product  ....................  23 
8.9 Concomitant Medications/Treatments  ................................ ................................ ..... 23 
9 Risks and benefits  ................................ ................................ ................................ ................  24 
9.1 Risks  ................................ ................................ ................................ .........................  24 
9.2 Benefits  ................................ ................................ ................................ ....................  25 
10 Assessment of Safety  ................................ ................................ ................................ ..........  26 
10.1  Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  ................................ ................................ ................................ ...............  26 
10.2  Adverse Events  ................................ ................................ ................................ ........  26 
10.3  Unanticipated Problems  ................................ ................................ ...........................  27 
10.3.1  Reporting Unanticipated Problems  ................................ ..............................  28 
Incidents or events that  meet the OHRP criteria for unanticipated problems will 
be reported using an unanticipated problem report form.  The 
unanticipated problem report form will include the following information 
when reporting an adverse event, or any other incident, experience , or 
outcome as an unanticipated problem to the IRB:  ................................ ...... 28 
10.4  Serious Adverse Events  ................................ ................................ ..........................  28 
10.4.1  Reporting SAE’s  ................................ ................................ ...........................  29 
10.5  Procedures in the Event of Abnormal Laboratory Test Values/Clinical Findings  ... 29 
10.6  Type and Duration of Follow -up of Subjects after Adve rse Events  ........................  30 
10.7  Halting Rules  ................................ ................................ ................................ ............  30 
10.8  Safety Oversight  ................................ ................................ ................................ ...... 30 
11 STATISTICAL CONSIDERATIONS  ................................ ................................ ....................  31 
11.1  Study hypotheses  ................................ ................................ ................................ .... 31 
11.2  Sample Size Considerations  ................................ ................................ ...................  31 
11.3  Planned Interim Analyses (if applicable)  ................................ ................................ . 31 
11.3.1  Safety Review  ................................ ................................ ..............................  31 
11.3.2  Immunogenicity or Effi cacy Review  ................................ .............................  31 
11.4  Final Analysis Plan  ................................ ................................ ................................ ... 32 
12 Source Documents and Access to Source Data/Documents  ................................ .............  34 
13 Quality Control and Quality Assurance  ................................ ................................ ...............  35 
14 Ethics/Protection of Human Subjects  ................................ ................................ ..................  36 
14.1  Ethical Standard  ................................ ................................ ................................ ....... 36 
14.2  Institutional Review Board (IRB)  ................................ ................................ ..............  36 
14.3  Informed Consent  ................................ ................................ ................................ .... 36 
14.3.1  Informed Consent/Assent Process (in Case of a Minor)  .............................  36 
14.4  Exclusion of Women, Minorities, and Children (Special Populations)  ....................  36 
14.5  Subject Confidentiality  ................................ ................................ .............................  36 
14.6  Study Discontinuation  ................................ ................................ ..............................  37 
14.7  Future Use of Stored Specime ns ................................ ................................ ............  37 
15 Data Handling and Record Keeping  ................................ ................................ ....................  38 
15.1  Data Management Responsibilities  ................................ ................................ .........  38 
               Fatty acid supplements alter biological signat ures in ASD                                                                                     Updated:  
CONFIDENTIAL                                                                                                                                                                22 May  2018 
 
  vi 
 15.2  Data Capture Methods  ................................ ................................ .............................  38 
15.3  Types of Data  ................................ ................................ ................................ ...........  38 
15.4  Study Records Retention  ................................ ................................ .........................  38 
15.5  Protocol Deviations  ................................ ................................ ................................ .. 38 
16 Publication Policy  ................................ ................................ ................................ .................  40 
17 Literature References  ................................ ................................ ................................ ..........  41 
 
               Fatty acid supplements alter biological signat ures in ASD                                                                                     Updated:  
CONFIDENTIAL                                                                                                                                                                22 May  2018 
 
 vii 
 PROTOCOL SUMMARY  
 
Title:              Fatty acid supplements alter biological signatures in children with Autism Spectrum  
            Disorder  
Background:  Fatty acid supplements are among the most popular complementary products  consumed by 
children with Autism Spectrum Disorder (ASD). Their use is driven by anecdotal evidence of 
benefit and a few small RCTs that demonstrated improvements in some externalizing behaviors 
in this population.1-3 Overall, there remains scant evidence for efficacy in treating the core 
symptoms of ASD like social -communication deficits and restricted and repetitive behaviors. 
Furthermore, very litt le is known about the biological signatures that are affected. Ove r-the-
counter (OTC) fatty acid supplements are plentiful and consist of varying percentages of 
gamma -linoleic acid (GLA, an omega -6 fatty acid), eicosapentaenoic acid (EPA, an omega -3), 
and docosahexaenoic acid (DHA, omega -3) and often include vitamins or plant extracts as well. 
Existing RCTs have tested varying combinations of fatty acids with conflicting results that likely 
stem from this variation. Because there are no approved medications  to treat the core 
symptoms of ASD, well -intentioned parents are r eaching for any product that promises 
improvement in their child, but they are giving these supplements without guidance as to their 
function, mechanism of action, or whether they are harmful or helpful in symptom management.  
 
For the proposed project, we will focus on preschool  and early school aged children because of 
the extensive literature indicating that a wide range of ASD therapies are maximally beneficial if 
they begin as early as in life as possible after diagnosis. This may be because neuroplasti city 
decreases significantly as children age, accompanied by the fact that DHA accretion in the 
developing brain displays a corresponding decline in rate with age .4 Along similar lines,  it has 
recently been reported that fatty acid bioavailability and  treatment effects in children may 
depend partially on body size (smaller children exhibit higher fatty acid levels for a given dose 
than larger children). Many pediatric medications are dos ed based on body weight; however, 
this concept has been virtually never applied to fatty acid supplementation. Aside from 
considerations about body size, only rarely are fatty acid supplements subjected to dose -
ranging trials where a variety of doses are e xamined simultaneously to identify the most 
efficacious and tolera ble. At most, a few studies have tested 2 doses vs placebo. These gaps in 
the literature represent a barrier to informing patients and clinicians about optimal dosing for a 
given child, with the end result that some children likely take a dose too small to  benefit.  
 
Population:  A randomized, fully -blind, placebo -controlled trial of 66 children ages 2 -6 years with recently -
diagnosed ASD. The tr ial will involve 90 days of treatment with one of 3 different doses  (25 mg, 
50 mg, or 75 mg twice per day , using child weight)  of Omega 3 -6 or (equal volume) placebo  
and will include 4 study visits.  
 
Study 
Objectives : 
 1) Optimize safety and bioavailability of Omega 3 -6 in a unique population of children with ASD; 
2) Evaluate the effect of Omega 3 -6 supplementation on  biological signatures of inflammation . 
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 8 
 1 KEY ROLES  
Key Personnel : Principal Investigator:   Sarah A. Keim, PhD, MA, MS  
 
Co-Principal Investigator:  Lynette K. Rogers, PhD  
 
 
Study Doctor  / Co-Investigator :  Daniel L. Coury, MD  
Institution : The Research Ins titute at Nationwide Children’s Hospital  
Center for Biobehavioral Health  
700 Children’s Dr ive 
Columbus, OH 43205  
Phone : 614-722-3182  
Fax: 614-722-3544  
 
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 9 
 2 BACKGROUND INFORMATI ON AND SCIENTIFIC RA TIONALE  
2.1 Introduction  
Although at least 1 in 68 U.S. children has been diagnosed with Autism Spectrum Disorder ( ASD), 
no approved medications e xist to treat the core symptoms . Atypical antipsychotics are commonly 
prescribed for irritability with ASD, but the side effects are significant, common, and of particular 
concern for very young children.5 Behavioral interventions can offer families approaches to live with 
the atypical behaviors and social deficits of ASD, but they are not cures. Because of the dearth of 
effective treatm ents, between 52% and 95% of families commonly try complementary therapies 
including fatty acid supplements, based largely on anecdotal evidence. To date, the results of 
efficacy trials testing fatty acid supplementation for ASD are mixed for several reaso ns including 
variation in the particular combination and dose of fatty acids tested and study design shortcomings 
including lack of blinding or placebo control. Another major reason for the lack of clarity is the very 
limited extent to which studies have e valuated potential biological signatures of interest in order to 
shed light on the pathways through which fat ty acids may exert their effect. This proposal will 
determine a primary pathway through which Om ega 3 -6 supplementation can benefit ASD 
symptoms, b y studying a leading candidate set of biological signatures and addressing related gaps 
in the literature that preclude successful efficacy trials.  
Fatty acid supplements are among the most popular complementary products consumed by 
children with ASD, driv en by anecdotal evidence of benefit and a few small RCTs that demonstrated 
improvements in externalizing behaviors. Because no approved drugs exist to treat the core 
symptoms of ASD, well -intentioned parents are reaching for any product that may help their  child. 
The implications are that fatty acid supplements are given to children without any evidence base as 
to their function, mechanism of action, or benefits versus harms. Overall, there remains scant 
evidence for efficacy of fatty acids in treating core  ASD symptoms from well -designed and 
adequately -powered RCTs, and very little is known about the mechanism(s) of action. Over -the-
counter (OTC) fatty acid supplements are plentiful and consist of varying percentages of oleic acid 
(n-9), gamma -linolenic aci d (GLA, n -6), eicosapentaenoic acid (EPA), and/or docosahexaenoic acid 
(DHA) and often include vitamins or other plant extracts. Existing RCTs have tested varying 
combinations and doses of fatty acids, and conflicting results likely stem from this variatio n. Recent 
evidence from our group and others suggest a combination of fish and borage oils providing 
supplementation of DHA, EPA and GLA (“Omega 3 -6”) is particularly promising compared to other 
formulations. Based on these foundations, a critical need exi sts to evaluate Omega 3 -6 for optimal 
dosing and changes in a biological signature that are related to ASD symptoms, before a rigorous, 
full-scale efficacy trial can be launched.  
 
Our long -term goal is to identify effective treatments for ASD.  The object ive of the  study  is to 
optimize safety and bioavailability of Omega 3 -6 in a unique population of children with ASD and 
evaluate the effect of Omega 3 -6 supplementation on biological signatures of inflammation.  A 
later study  to be described in a future pro tocol will relate these changes to core ASD symptoms. 
Our overall hypothesis for the line of research is that Omega 3 -6 will alter biological signatures 
related to inflammation in a manner that correlates to ASD -related behaviors. Our hypotheses 
were formu lated based on data from our Preemie Tots study and other published data which 
suggest that the inflammatory markers, IL -1β, IL-2, and IFN γ are consistently elevated in 
children with ASD and decreases in these markers correlate with ASD symptom improvement . 
The rationale for the proposed research  is that its successful completion will provide the 
infrastructure and endpoints necessary to support a  future efficacy trial to give parents and 
clinicians unequiv ocal evidence for fatty acid supplementation for AS D. 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 10 
 2.2 Biological Pathways and Mechanisms  
Fatty acids (FA) have diverse and complex biological functions. Long chain polyunsaturated fatty 
acids of the omega -3 series have been extensively studied and demonstrate anti -inflammatory 
properties affecting multipl e pathways. The omega -3 DHA comes from fatty fish or algal sources, is 
the primary neuro -active fatty acid in the brain, and is a key player in neurotransmitter function, 
synaptogenesis, gene expression, membrane fluidity, neurogenesis, neuroplasticity, an d anti -
inflammation .6-11 EPA, also from fish oil, is often included in omega -3 fatty acid supplements and 
has triglyceride lowering properties and anti -inflammatory properties similar to DHA. GLA is a 
shorter -chain fatty acid of the omega -6 series derived from plant sources including borage and 
evening primrose. GLA is a precursor to fatty acids such as arachidonic acid (AA) which is essential 
for lipid signaling and hormone synthesis. Biologically available GLA is q uickly co nverted to dihomo -
γ-linolenic acid (DGLA), which now has been shown to have substantial anti -inflammatory 
properties unique among longer chain n -6 fatty acids .12 As omega -3 and omega -6 fatty acids share 
common desaturation and elongation enzymatic pathways, combinations of these fatty acids can 
effectively compete for these enzymes creating a ph ysiologic balance rather than a shift toward one 
pathway or the other. The mechanisms associated with the anti -inflammatory effects of long chain 
fatty acids are still not completely understood but include direct binding to g -coupled protein 
receptor 120 ( GCPR120) or peroxisome proliferator -activated receptor gamma (PPAR γ) to inhibit 
MAPK or NFkB activation, production of alternative lipid products such as resolvins and protectins, 
and changes in membrane composition that alters ligand binding to cytokine or toll -like receptors.   
Children with ASD have been shown to exhi bit altered fatty acid metabolism; several investigations 
have shown decreased levels of DHA, EPA, and AA in these children. The reason for these 
decreases i s not completely clear but may be due to a combination of diet differences, altered 
absorption, def ects in fatty acid synthesis because of polymorphisms in fatty acid desaturase genes 
(FADS2) or other metabolic alterations .13-15 Since all of these FAs contribute to important biological 
functions, influence anti -inflammatory pathways, and enhance anti -inflammatory mechanisms, we 
speculate that decreases or deficiencies in these FAs directly contribute to the increased 
inflammation observed in ASD patients.  
2.3 Advantages of Fatty Acid Combination T herapies  
DHA has been  the most widely investigated fatty acid for treatment of mental disorders and has 
demonstrated efficacy in patients with depressive or schizophrenic symptoms. In addition, DHA 
reduces the risk of mild or significant mental delay in extremely preterm infan ts.16 However, DHA 
alone appears to exhibit little or no benefit in treating aberrant behavioral symptoms .17 Adding EPA 
to DHA (“EPA+DHA ,” usually in the form of fish oil) has been evaluated in 4 RCTs for benefi ts to 
individuals with ASD. One small trial (n=13) showed benefit to language and maladaptive 
behaviors ,3 2 other small trials reported benefits limited to hyperactivity ,2,18 and the most recent trial 
reported worsening externalizing behaviors .19 EPA+DHA has been shown to be moderately 
efficacious in reducing symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in large RCTs 
(meta-analysis standardized mean difference=0.31, 95% CI: 0.16, 0.47) .20 The combination of 
Omega 3 -6 holds significant promise to be more efficacious than EPA+DHA for ASD for several 
reasons. Direct comparison of the e vidence for Omega 3 -6 vs EPA+DHA for treating ADHD in a 
recent meta -analysis reported larger effect sizes and more consistent benefit for omega 3 -6 than for 
EPA+DHA (standard difference in means -0.31 favoring omega 3 -6-9 (CI: -0.46, -0.16)) .21 Among 
the largest of these studies, Richardson e t al. found a >0.5 -standard deviation reduction in global 
Conners’ Teacher Rating Scales scores among children randomized to Omega 3 -6 for 3 months 
compared to placebo, and Sinn et al. found medium -strong effects of supplementation on parent 
ratings of ADH D symptoms .22,23 However, only 2 placebo -controlled RCTs have tested Omega 3 -6 
formulations for developmental or behavioral outcomes other than ADHD: one study demonstrated 
benefits for school -age children with Deve lopmental Coordination Disorder on reading and spelling 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 11 
 achievement and acr oss multiple behavioral domains , and our Preemie Tots study demonstrated 
reduced autistic behaviors, compared to a placebo.22 
2.4 Inflammation i n Patients with ASD  
ASD is characterized by pervasive deficits in social communication accompanied by stereotypic 
behaviors. The severity of these symptoms varies widely in ASD and can be accompanied by 
significant cognitive impairment. The etiology of ASD  remains unclear, but it has both genetic and 
environmental contributors which  impact inflammatory pathways. Inflammation has been well 
characterized in patients with ASD with increases in inflammatory cytokines and chemokines both in 
the circulation and C SF.  Interleukin (IL) -1β is an acute response cytokine produced by immune 
cells and acts through targeting cognate receptors present on the cell membrane in tissues . 24 IL-1β 
can cross th e blood -brain –barrier, inducing increased permeabil ity or be produced by astrocytes 
and microglia in the brain.  Increases in IL -1β in neurological tissues, causes increased exocytosis 
of several neurotransmitters, resulting in increased excitability, anxiety, and activation of the 
HPA.25,26 Interleukin (IL) -2 has been extensively studied in the context of brain development and T -
cell fate .27 IL-2 acts in a trophic manner during development and loss of IL -2 causes deficits in 
learning and memory processing in animal studies. Alternatively, IL -2 regulates immunological 
homeostasis, self -tolerance and T cell development and function implying dysregulation may play a 
significant role in neurological auto -immune diseases .24,27 Interferon gamma (IFNγ ) is produced 
primarily by epithelial cells and is the acute phase  cytokine produced in  response to viral infections. 
Besides its effects in mediating viral  immunity, IFN γ also modulates adaptive immunity through 
skewing T cell responses to an inflammatory Th1 phenotype .28-30 A recent meta -analyses of clinical 
studies in ASD patients revealed that IL -1β and IFNγ  were b oth elevated in  virtually every study 
included (IL-2 was not evaluated) and we observed similar increases in IL -1β and IFN γ in our 
Preemie Tots study.31  Of most importance, w e observed lower levels of IL -1β, IFN γ, and IL -2 in the 
children that were supplemented with the Omega 3 -6 formulation.  
2.5 Eviden ce for the Need for Early Intervention and Tailored D osing  
For the proposed project, we will focus on young  children  ages 2 to 6  because of the extensive 
literature indi cating that a wide range of ASD therapies are maximally beneficial if they begin as 
early in life as possible after diagnosis . This may be because neuroplasticity decreases significantly 
as children age, accompanied by the fact that DHA accretion in the de veloping brain displays a 
corresponding decline in rate with age .4  Along similar lines, it has recently been reported that fatty 
acid bioavailability and treatment effects in children may depend partially on body size (smaller 
children exhibit higher  fatty acid levels for a given dose than larger children). Many pediatric 
medications are dosed based on body weight; however, this concept has been virtually never 
applied to fatty acid supplementation. Aside from considerations about body size, only rare ly are 
fatty acid supplements subjected to dose -ranging trials where a variety of doses are examined 
simultaneously to identify the most efficacious and tolerable. At most, a few studies have tested 2 
doses vs. placebo. These gaps in the literature represe nt a barrier to informing patients and 
clinicians about optimal dosing for a given child, with the end result that some children likely take a 
dose too small to benefit.  
2.6 Consideration of Comorbidities C ommon in ASD  
In addition to the social -communication a nd behavioral features of ASD, many individuals with ASD 
have other comorbidities that impact overall health and daily functioning including at least 34% have 
gastrointestinal problems like constipation, 34% are overweight and 18% are obese . Theoretically,  
these conditions may modify the effect of fatty acid supplementation on core ASD symptoms by 
inhibiting gastrointestinal absorption of the supplement or by sequestering a portion of ingested fatty 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 12 
 acids in adipose tissue rather having them biologically av ailable. A full -scale efficacy trial will likely 
need to consider these possible treatment modifiers when establishing inclusion/exclusion criteria, 
setting a target sample size, and selecting dose(s).  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 13 
 3 STUDY  AIMS  
 
The aims of this project are to:  
 
1)  Opti mize safety and bioavailability of Omega 3 -6 in a unique 
population of children with ASD.   
  
2)  Evaluate the effect of Omega 3 -6 on the biological signatures of 
inflammation (IL -1β, IL -2, IFNγ).   
  
 
 
3.1 Study Outcome Measures  
 
Primary Endpoint (Aim 1): Group  differences in bioavailability (each fatty acid as a percent of total 
erythrocyte fatty acids at the end of the trial) and safety (number of and types of adverse events) . 
 
Primary Endpoint (Aim 2): Changes in the biological signatures (IL-1β, IL -2, IFNγ ) from baseline 
to the end of the trial.   
  
 
 
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 14 
 4 STUDY DESIGN  
4.1 Study Participants  
This single -site study will be conducted at Nationwide Children’s Hospital (NCH). We will recruit 
from among patients who have received an ASD diagnosis  at NCH  within the prior 6 months . We 
expect large numbers of available and interested participants because NCH diagnoses over 800 
children with ASD each year, and recruitment into past treatment studies in this patient population 
has been very successful . Children evaluated at NCH for ASD undergo a comprehensive 4 -6 hour 
evaluation with a developmental pediatrician, psychologist, and speech pathologist covering all 
DSM -5 defined ASD criteria, cognitive ability, adaptive behavior, and other behaviors commonly 
comorbid with ASD like h yperactivity, based on trained clinician evaluation and parent report. 
Children who are given the ASD diagnosis including a score on the gold standard Autism Diagnostic 
Observation Schedule -2 (ADOS -2) in the “autism” range which is on the severe end of the  
spectrum, and who meet the other eligibility criteria for the study will be recruited. We focus on 
children in t his range to reduce the heterogeneity of the sample and to maximize the probability of 
benefit.  
After diagnosis, children will be evaluated for  trial eligibility based on medical record review and 
parent interview. Paren ts will be contacted via letter, phone , and/or email  to discuss participation.   
Inclusion criteria: age 2 -6 years, ASD diagnosis at NCH within prior 6 months with an 
ADOS -2 score in the “autism” (severe) ran ge, English is primary language.  
Exclusion criteria:  fatty acid supplements in the past 6 months, consume fatty fish >3 
times/week, still breast or formula feeding; quadriparesis; deafness; seizure disorder, 
blindness; bleeding disorder; autoimmune disorders including Type I diabetes; Fragile X, 
Rett, Angleman Syndromes; Tuberous Sclerosis; feeding problems precluding consumption 
of the  supplement; ingredient allergy ; planned surgeries scheduled within the timeframe of 
trial part icipation.  
 
Additionally,  and as part of the informed consent process, Study Staff will ensure that parents have 
a good understanding of study procedures and are able to comply with study procedures for the 
entire length of the study.  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 15 
 5 STUDY ENROLLMENT , TREATMENT ASSIGNMENT,  AND WITHDRAW  
5.1 Enrollment  
The target sample size for  this dose -ranging  study  is 66 children. The study team will be alerted by 
the electronic medical record system when an autism diagnosis is made at NCH  for a potentially 
eligible child . The system is updated nightly and study staff will be electronically notified of new 
diagnoses biweekly . Before contacting potential participants for recruitment purposes, the medical 
record will be used to prescreen potentially eligible participants. Dur ing this process, study staff will 
examine the ASD diagnostic evaluation to determine if the chil d meets the inclusion criteria and is 
not excluded due to any exclusion criteria. The medical record will be screened for eligibility 
information, but eligibil ity will also be confirmed with a legal guardian prior to enrollment.  
5.1.1  Medical Record Data  
The following data items will be collected from the child’s medical record:  
 Results of the comprehensive ASD evaluation conducted at the NCH Child Development 
Cente r including scores from developmental and behavioral testing and clinical summary 
notes  
 Related diagnoses including gastrointestinal disorders and other developmental and 
behavioral diagnoses (e.g., ADHD) and dates of diagnoses  
 Demographic and participant characteristics (Date of birth, Sex, Race, Ethnicity, Medical 
insurance payor, Language, Life status, Multiple birth)  
 Percent no shows to appointments  
 Food allergies  
 Current medication list  
 Contact information  
5.1.2  Recruitment Mailing  
An introductory letter and  informational study brochure will be sent to all eligible families after the 
electronic medical record screening phase. This letter will briefly introduce the study and be signed 
by Dr. Keim  and Dr. Rogers . The introductory letter and study brochure will briefly describe the 
purpose of the study and will provide contact information for study staff.  This informational  mailing  
will request change of address information from the post office to identify families who have recently 
moved. Although we expect  up-to-date contact information to be available in the electronic medical 
record due to the recent NCH  diagnostic appointment,  contact information may be verified and/or 
attempts to locate unreachable families (e.g., those with outdated contact information on file) will be 
made using a web -based online search service that provides a fast and effective way to look -up or 
verify contact information about a person, phone number or address of interest. Contact information 
will be verified using names, addresses, and  phone numbers.  
 
 
5.1.3  Recruitment Contact  
Study staff  will phone the family approximately one week after mailing the introductory letter and 
study brochure to further assess eligibility and gauge general interest in participating.  Study staff 
will use the pho ne script devised for this study as a conversation guide. During this phone call, 
study staff will provide a description of the study and its requirements. If the family is interested in 
participating, study staff will describe the study to the legal guard ian and ask if the guardian and 
child are interested in coming into Nationwide Children’s Hospital to enroll in the project. During this 
appointment, study s taff will meet with the guardian to provide detailed information about the study 
and answer any que stions the guardian  may have. If the parent is interested in enrolling his/her 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 16 
 child and the child meets all eligibility criteria and is not excluded based on the exclusion criteria, 
study staff will guide the parent through the informed consent process . Participation or refusal to 
participate in the study will not affect the child’s  entitlement to clinical care.  
This study intends to enroll children  a special population and will accordingly adhere to additional 
protections specified under  45 CFR Part 46 S ubpart D – Additional Protections for Children Involved 
as Subjects in Res earch (45 CFR Part 46.401 -409).  
5.1.4  Treatment Assignment  
Study staff will develop a detailed Standard Operating Procedure (SOP) for Randomization and 
Blinding, and Emergency Unblinding Procedures. This SOP will describe how  the randomization 
scheme  will be generated and that the scheme will be stored in a locked cabinet.  
5.1.5  Randomization and Masking Procedures  
Randomization will involve a stratified block design of randomly varying block s izes of 6 and 12 
with equal allocation to each of the two study arms. A pseudorandom number generator in the 
statistical software package R will be used by Dr . Rausch to implement randomization, and he 
will maintain the randomization sequence such that it is unavailable to other team members. 
Randomized block sizes will be generated within each of 4 strata formed by crossing 2 
stratification variables: age (2 -3 vs 4 -6 years) and sex. This stratification design minimizes 
confounding across groups due to the stratification variables. This block design assures a 
balanced allocation across the 2 study arms.  Randomly varying block sizes  reduces the chance 
that study staff can guess the next group assignment and thus minimizes unconscious bias in 
patient allocatio n in the RCT. Furthermore, having an experienced statistician not otherwise 
involved in study operations produce the randomization scheme will help maintain blinding 
which is critical to the integrity of the trial and the value of the findings. Investigato rs, staff, 
parents , and participants will be blind to treatment assignment until all data are collected 
whereupon only those involved in analysis will be unblinded as needed.  One to two staff people  
(Adherence Aides) will be unblind and have the sole role of counseling families with strategies 
for protocol compliance (encouraging children to ingest the assigned volume) during scheduled 
phone calls. In order to perform this duty,  they will need to have access to information about 
assigned dose.   
 
 
Dr. Rausc h will create tamper -resistant opaque envelopes. These will be sequentially numbered 
with study ID numbers (a sequence prepared for each of the 4 total strata).  These will be placed 
in sequence in 4 labeled and secured boxes, one for each stratum. Each tim e a participant is 
recruited the next envelope in order will be drawn from the stratum specific box that corresponds 
to that participant’s stratum. Inside each envelope will be a designation (e.g., one of six letters of 
the alphabet) for assignment to trea tment or placebo and at which dose . This designation will not 
be revealed to families.  The participant will be registered in the electronic medical record system 
and the study doctor will print and sign the prescription . The participant study ID will be ad ded to 
this prescription. Study staff will alert the NCH Investigational Drug Service as to the enrollment 
and randomization of the participant  and the participant’s weight . IDS will be given the signature 
page of the consent form and the prescription. IDS will have access to the randomization scheme 
so they can match the letter designation and ID to the appropriate treatment and dose. IDS will 
prepare the prescription and the oil will be distributed directly from the pharmacy to the family  to 
prevent unbli nding of study staff .  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 17 
 5.1.6  Emergency Unblinding  
An emergency unblinding SOP also will be generated. Only the IRB or PI are allowed to authorize 
early unmasking in the event of emergency. Otherwise, the randomization assignments will be kept 
secure until closur e of the study.  
5.1.7  Withdraw  
Study participation will be discontinued under the following circumstances:  
 
1. PI or Study Doctor believe it is in the best interest of the participant;  
 
2. Participant’s  legal guardian requests withdraw from the study;  
 
3. Any clinical AE , laboratory abnormality, intercurrent illness, or other medical condition or 
situation occurs such that continued participation in the study would not be in the best 
interest of the child , as deter mined by the PI and Study Doctor; or  
 
4. Development of any e xclusion criteria may be cause for discontinuation.  
 
5. Study instructions are not followed, participation in the study may also be stopped  
Withdrawal from the study will not affect the receipt of clinical care at NCH. If the study is halted for 
any reason, p articipants will be instructed to discontinue taking the assigned treatment and return 
the unused portion to study staff .  Participants who choose to discontinue taking the assigned 
treatment during the study will continue to be followed for assessment of the outcomes, and their 
discontinuation will be recorded in the study database. Participants who continue to participate but 
are found to have low adherence to the assigned treatment oil  or placebo oil will not be withdrawn 
and will continue to be followed . 
5.1.8  Handling of Withdrawals  
The study will continue to  collect safety data on any participant  discontinued because of an AE or 
serious adverse event ( SAE). If a participant stops taking the assigned oil, the participant  will be 
asked to continue scheduled ev aluations .  
5.1.9  Termination of Study  
Because intervention s based on products with similar composition have  not found harm to young 
children, it is not anticipated that the study would need to be terminated due to development of 
toxicities or adverse events du e to the intervention.  However, the study will be terminated if the PI, 
Study Doctor,  IMC, or IRB conclude  based on their findings  that termination is in the best interests 
of the participants.  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 18 
 6 STUDY PROCEDURES AND  SCHEDULE OF EVENTS  
Participation will last for 90 days. The study will involve three in -person  study visits at 0, 45 and 90 
days  and one remote “e -visit” at 25 days . Visit 1 will involve informed consent, randomization, 
gathering anthropometric data, parent completed questionnaires, distributi on and explanation of the 
study diaries, a 3 mL blood collection, and distribution of the treatment oil /placebo  oil. This visit will 
last approximately 90 minut es. Day 25  e-visit will review the  study diaries to date, assess 
compliance, barriers to partici pation, and adverse events . Visits 2 and 3 will last approximately 60 
minutes . They  will involve returning all  oil bottles distributed at the prior in -person visit , review of 
study diaries, assessment of compliance and adverse events, parent  completed ques tionnaires, 
and a 3 mL blood collection . In addition, study staff will check in with families at four other time 
points  (Day 5  +/-3 days , Day 35  +/-7 days , Day 60 +/-7 days , and Day 80  +/-7 days ) to assess 
compliance, adverse events, and barriers to partici pation. We  will ask families for updated contact 
information at the end of each study visit, as well as to provide up to three additional contacts (e.g., 
friends/family) who we may contact if their contact information becomes outdated.  
6.1 Visit 1 (Day 0)  
The enrollment visit will consist of the following activities:  
 
Informed Consent:  See Informed Consent section . 
 
Randomization: After consent, families will be randomized . See Randomization and Masking 
Procedures .  
 
Blood Collection: To measure baseline fatty  acid levels, a trained pediatric phlebotomist will draw 3 
mL whole blood into a purple top tube.  
 
Anthropometrics: Child weight  and height will be measured using SECA scales  and stadiometer  to 
inform IDS in calculat ing the assigned dose . If child cannot be accurately weighed, staff will use 
most recent weight found in medical record system  (EPIC) . 
 
Parent Perception of Treatment Group : Parents will be asked what treatment group they believe  
their child will be in . 
 
Barriers to Participation: The family’s intentions to complete the study, attend the next study visit, 
and give their child the assigned oil on a daily basis throughout study duration . 
 
Parent Interview: A parent interview will gather baseline child and family characteristics (sex, age, 
socioeco nomic index) to characterize the sample and verify comparability across groups. In 
addition, parents will complete the Baylor fatty acid -specific food frequency questionnaire  as an 
interview  to measure usual dietary intake of long -chain fatty acids. Finall y, parents are asked to 
report on current medications , upcoming surgeries,  as well as use of compl ementary and behavioral 
therapies or programs.  
 
Supplement Dispension : Study staff will counsel families on instructions for taking the daily 
treatment oil /placebo  oil, how to record each dose in a provided daily study diary, and reporting 
adverse events. IDS will dispense (4) 8 oz. bottles of assigned oil, which will be ample for the 
majority of  participants. If child weighs more than 32 kg, an extra bottle w ill be dispensed at Visit 1 
and Visit 2. IDS will dispense the assigned oil directly to the family and will further instruct on  taking 
the assigned oil . 
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 19 
 Compensation :  At the conclusion of the visit, participants receive $ 75 in compensation for their time  
and a Children’s Hospital Parking Garage Pass ($2). Children are given a developmentally -
appropriate children’s book or small toy (value =$5).  
 
Visit scheduling:  Study staff will schedule for in-person visits 2 and 3 . 
 
6.2 E-Visit  (Day 25   +/- 7 days  phone co ntact ) 
This visit will be a remote “ E-Visit” via phone and will include the following activities:  
 
Parent Perception of Treatment Group and Adherence : Parents will be asked what treatment group 
they perceive their child to be in and to estimate what propor tion of doses they administered out of 
the desired number and what proportion of the assigned oil they estimate their child usually 
consumed. Study staff will review study  diaries use with the parent and will probe for any problems 
encountered that reflect  acceptability, tolerability or compliance. Study staff will request that the 
caregiver take photos of each study diary page used thus far. Caregiver  will email or text study staff 
with these photos.  
 
Adverse Events:  Parents will be asked if the child has  any health or behavior changes since the last 
communication. We will use a modified version of the Safety Monitoring Uniform Report 
Form  (SMURF ) to document adverse events.  
 
Barriers to Participation: The family’s intentions to complete the study, attend the next study visit, 
and give their child the assigned oil on a daily basis throughout study duration; as well as any 
anticipated barriers to study participation are assessed during each contact with the family.  
 
To simplify our recruitment and retention  materials, participants will  see that there are 3 in -person 
visits  and 5 follow up phone calls . This “ E-Visit Day 25 ” phone call will be one of the five follow -up 
contacts.  
6.3 Visit 2 (Day 45  +/- 14 days )  
This visit will consist of the following activities : 
 
The following activities will follow the same procedures as for Visit 1: Blood Collection , Parent 
Interview, Parent Perception of Treatment Group and Adherence, Adverse Events, Barriers to 
Participation.   
 
Supplement Return: Families will return all pre viously dispensed oil bottles to IDS for calculating of 
used/unused portion .  
 
Supplement Dispension:  IDS will dispense (4)  8 oz bottles of assigned oil  (extra bottle will be 
dispensed if child is over 32 kg) . IDS will dispense the assigned oil directly to  the family and will 
further instruct on taking the assigned oil.  Completed study diary pages will be scanned and diary 
returned. New diary dispensed as necessary.   
 
Compensation : Compensation will be the same as for Visit 1. In addition, f amilies will receive $2 for 
every study diary returned at the study visit (1 diary page covers a 2-week  period).  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 20 
 6.4 Visit 3 (Day 90 +/- 14 days )  
The final visit will consist of the following activities:  
 
The following activities will follow the same procedures as for Visi t 2: Blood Collection, Parent 
Interview, Parent Perception of Treatment Group and Adherence, Adverse Events, Supplement 
Return.  
 
Anthropometrics: Child weight and height will be measured using SECA scales and stadiometer.   
 
Supplement Return: Families will  return any empty assigned oil  bottles and any partially used or 
unopened assigned oil  bottles to IDS.  
 
Compensation :  Compensation will be the same as for Visit 2, except i f families completed all 4 
study visits  (1 of which is the E -Visit) , they will rec eive an additional $20 incentive.  Families will 
receive $2 for every study diary returned at the study visit (1 diary  page  covers a 2-week  perio d). 
 
6.5 Additional Routine Communication  (throughout participation)  
In addition to the study visits, study staff w ill routinely check in with families at least 5 times (more if 
a family requires additional support) spaced between the visits  to assess adherence, adverse 
events, and barriers to participation. These check s may take place in person, over the phone, or 
through email or text , depending on family preference  and ease of communicating .  
 
Families will be reminded of scheduled/upcoming appointments via phone, email and/or text (based 
on family preference). Attempts will be made via phone, email, text, and/or mai l to contact families 
who do not show for their scheduled visits. During these communications, both remotely and in 
person, parents may be asked to estimate what proportion of doses they administered out of the 
desired number and what proportion of the ass igned oil they estimate their child usually consumed.  
Interim study diary  data will be collected in the form of photos (of each completed study diary page) 
as often as possible from caregiver via email or text.  This will assist in keeping families engaged in 
study diary use and will provide data if study diaries cannot be returned at in -person visits. Study 
staff will work with the family to increase adherence where possible. We will use the modified Safety 
Monitoring Uniform Report Form  (SMURF ) to document  adverse events. Children who do not return 
for the 2 in -person follow up visits will be considered lost to follow -up, but attempts will be made to 
contact them via phone at these pre -prescribed intervals.  
 
6.6 Rationale for Data Collection  
Data are collected to: 
 
1) Assess demographic and other participant characteristic s, thereby allowing a check of the 
randomization procedure  and to report on the composition of the sample ; 
2) Assess the outcomes of interest ; and  
3) Determine the feasibility of and aims for the next s tage of research . 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 21 
 7 LABORATORY EVALUATIO NS  
7.1 Specimen Preparation, Handling, and Shipping  
Instructions for the preparation, handling, and storage of specimens are explained clearly in the 
study’s SOP, including required temperatures, aliquots of specimens, wh ere they will be stored, and 
how they will be labeled. Samples will be stored at -80oC until analysis in Dr. Lynette Rogers ’ 
laboratory in the Center for Perinatal Research. All laboratory analyses of biospecimens will be 
conducted by Dr Rogers. Serum and RBC samples will be collected from patients at 3 time points to 
determine bioavailability of the supplement in this specific population and to measure the effects of 
treatment on biological signatures.  
 
Fatty acids will be measured in patient red blood ce lls by standard protocols using gas 
chromatography and will include : capric (10:0), lauric (12:0), myristic (14:0), palmitic  (16:0) , 
palmitoleic (16:1n -7), steric  (18:0) , oleic  (18:1 n -9), vaccenic (18:1n -7), linoleic  acid (18:2 n -6), 
-linolenic acid (18:3 n -3) , -linolenic acid (18:3 n -6), dihomo γ -linolenic acid (DGLA, 20:3  n-6) 
arachidonic (AA, 20:4n -6), eicosapentaenoic acid ( EPA,  20:5 n -3), and docosahexaenoic acid 
(DHA , 22:6 n -3).  High and low controls will be run with each bat ch analysis and a run will be 
considered non -valid if the controls are greater than 2 standard deviations from the mean values 
for DHA, EPA, and GLA.  A non -valid analysis will be discarded and the samples will be re -
analyzed.  Biological signatures will i nclude the cytokines IL-1β, IL-2, IFN γ.  These inflammatory 
cytokines will be measured using an ELISA based technology offered by Meso Scale Discovery. 
   
Any remaining specimens will be maintained in a secured freezer in the Center for Perinatal 
Research, or Center for Biobehavio ral Health (depending on space availability) at NCH for future 
research use.  Only the investigators for this study will have access to these specimens and 
permission for future use.  The consent form for the study will state that leftover specimens may be  
used for studies of ASD, child development or nutrition conducted only by the investigators for the 
present study.  
 
7.2 Biohazards  
Blood samples will be obtained from study participants at each visit.   This service will be 
provided by the Outpatient Lab  at Na tionwide Children’s Hospital .  As a back -up, Clinical 
Research Services nursing staff can perform this duty.  All personnel will be trained in the 
handling of biohazardous samples and are experienced in working with children in these 
situations.  Blood samp les will be separated prepared for storage by personnel trained in 
handling  hazardous  biological samples.  All procedures will follow Good Clinical Practice and 
federal, state, and institutional regulations and guidelines.  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 22 
 8 INVESTIGATIONAL PROD UCT 
8.1 Acquisit ion 
Nordic Naturals Complete OmegaTM liquid  (treatment oil) will be provided by Nordic Naturals 
(Watsonville, CA).  Bulk canola oil will be purchased from Welch, Holme and Clark Co., Inc. (Newark, 
NJ).  The PI will request an initial supply of the treatmen t oil and placebo oil to be delivered to IDS 
prior to the study commencing. Additional products will be requested as needed. All treatment oil will 
come from the same manufacturing batch. A sufficient supply of the oils will be maintained in IDS 
throughout  the study.  
8.2 Formulation, Packaging, and Labeling  
The treatment oil  will be provided by Nordic Naturals in blue glass bottles. It is available  over-the-
counter. The Nordic Naturals Complete OmegaTM liquid  contains in each 1 tsp ( 5ml):  
 
 
 
Welch, Holme and Clark  Co., Inc.  will provide the canola oil placebo. Although f atty acid 
composition varies slightly with  each lot of the canola oil,  the dist ributor provides average fatty acid 
composition per 2.5  ml (2.3g) daily serving. Specifically, each 2.5  ml serving of the canola oil 
placebo contains 124  mg of palmitic acid, 39  mg stearic acid, 513  mg linoleic acid, 225  mg linolenic 
acid, and 1346  mg olei c acid.  The bulk canola  oil placebo will be shipped from the distributor in  5-
gallon shipments to NCH IDS who  will mix the oil with lemon oil at  1:66.6 (1.5 mL of lemon oil per 
100 mL of canola oil) . In this way , the treatment oil and placebo  oil will be  indistinguishable  in terms 
of appea rance, smell  and taste. IDS will bottle  and cap  the placebo  oil in identical bottles  and caps  
as the treatment oil . 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 23 
 8.3 Dispension  
Each participant who is 32  kg or less will receive four 8 oz bottles of assigned oil at Visits  1 and 2 . An 
additional bottle will be dispensed at T1 and T2 if participant is over 32  kg. At the initial  dispension , a 
prescription will be delivered to IDS , signed by the Study Doctor . At this point, IDS will select the 
appropriate product,  determine th e appropriate dose based on child’s weight and group randomized , 
and place a label conducive to Ohio BOP and FDA regulations is placed on each bottle  of the 
treatment oil or placebo  oil before  being dispensed . Additionally, the amount of product dispensed to 
a participant is recorded in an overall master log, maintained by IDS.  No information on the bottles  
will indicate which product is contained in them upon dispension from IDS.  
 
In the case of a participant requiring additional supplies of assigned oil (spillage, losing a bottle), 
interim dispensions can occur via shipping product to the family’s home. One 8 oz. bottle (or more if 
necessary)  will be provided in these instances.  
8.4 Product Storage and Stability  
The treatment oil  and placebo oil will be kept in a dry, secured environment, controlled  and 
monitored for the appropriate temperature. The expiration dates on the products will be monitored 
by IDS to ensure product freshness.  The treatment oil  and placebo oil will be kept refrigerated to 
maximize freshness. All families  will be instruct ed to keep their bottles refrigerated.  
8.5 Dosage, Preparation and Administration  
Children are randomized to receive 25 mg, 50 mg, or 75 mg of Omega 3 -6 (treatment group ) or equal 
volume of placebo  oil to be administered twice per day by mouth for 90 day s. 
8.6 Modification of Investigational Product  
No circumstances are known for which the dose should be modified.  
 
8.7 Accountability P rocedures for the Investigational Product  
IDS will monitor the receipt of the  treatment oil  and p lacebo oil from the manufacturers, dispension 
of the treatment oil  and placebo oil to participants, the return of the treatment oil  and placebo  oil 
from participants, and the appropriate disposal of any unused assigned oils .  
8.8 Assessment of Subject Complian ce with the Investigational Product  
Parents will be provided with a series of paper diaries  and instructions to record whether the child 
consumed the assigned oils each day and what proportion they consumed each day as well as any 
acceptability  or tolerab ility issues. Set of s tudy diaries will be dispensed at Visit 1 . Pages of this 
diary will be scanned and diary will be returned . A new set of study diaries can be dispensed at 
follow up visit or by mail as needed . Photos of any completed study diary pages will be requested 
from caregivers during follow up contact. Caregivers will text or email photos of these pages to 
study staff. See Study Procedures and Schedule of Events for procedur es for assessment of 
compliance.   
8.9 Concomitant Medications/Treatments  
There are no restrictions on what drugs or treatments may be concomitant with the study 
intervention.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 24 
 9 RISKS AND BENEFITS  
9.1 Risks 
All of the research related procedures, surveys, and questionnaires, are designed to meet the 
definition of “minimal risk” in the fe deral regulations [§45 CFR 46.102(i)] and to be reviewed by IRBs 
under §45 CFR 46.404 “Research not involving greater than minimal risk.” Minimal risk as defined 
in the federal regulations means “that the probability and magnitude of harm or discomfort 
anticipated in the research are not greater, in and of themselves, than those ordinarily encountered 
in daily life or during the performance of routine physical or psychological examinations or tests.” In 
addition, the Study Staff is committed to minimizing r isks even when the risks are minimal.  
 
The informed consent process will take place in private. Questionnaires will be structured to avoid 
creating discomfort for the research participants; and participants will be reminded at each data 
collection encount er that participation is voluntary, that they have the right to withdraw from the 
research project at any time, and they may refuse to answer or may skip any question.  
 
Experienced pediatric phlebotomists staff will perform biospecimen collections that inv olve minimal 
discomfort or pain. All staff involved in collection of biospecimens will be credentialed accordingly. 
The physical risks of drawing blood by placing a needle in a vein may cause pain, lightheadedness, 
bleeding, bruising, or swelling at the pu ncture site.  Infection is a rare possibility.  No alternatives to 
blood collection exist to reliably assess fatty acid and inflammatory status in humans.  
 
The risks of collecting and storing linked clinical data and biospecimens are primarily psycho -socia l. 
Developing coding strategies to mitigate these risks is a fundamental ethical requirement of the 
study. Potential harm could result from a breach of confidentiality. One of the primary concerns is 
that employment and insurance discrimination might resul t from exposure of information about 
health history, genetic makeup, or familial predisposition to disease. The risk is minor, especially 
since unique participant identifiers will not be stored with biospecimens.  
The Nordic Naturals Complete OmegaTM liquid  product contains a combination of fish and borage 
oils.  These oils include several LCPUFAs including eicosapentaeonic acid (EPA) and gamma -
linolenic acid (GLA).  Although giving EPA to preterm infants (i.e., children much younger than 
those eligible in t his study) has been found to pose some risk related to poorer growth in a single -
site study that has not been replicated,32 numerous other infancy and post-infancy studies using 
EPA have not reported adverse effects. Because EPA also can increase bleeding time, albeit 
generally clinically insig nificantly, children with existing bleeding disorders will be excluded from 
participation. Children wi th planned surgeries will be excluded.  
The presence of borage oil in the supplement contributes the GLA content. Most of the safety 
information available about GLA comes from studies that used evening primrose oil, another major 
source of GLA. Animal studies have shown no toxic or carcinogenic effects .33 Previo us human 
studies have involved over 4,000 individuals, and no significant adverse effects have been reported. 
There have been two case reports of excessive intake of borage oil or other GLA -containing 
supplements causing worsening seizures in epileptics, b ut there have been no published cases or 
studies since these reports were published in 1981.34 Although the likelihood of thi s occurring in the 
present study is very low, children with a  seizure disorder  will be excluded from the study.  A 2004 
study of 238 preterm neonates evaluated an infant formula with fish and borage oil compared to a 
vegetable oil formula fed to infants fo r 9 months.35 Daily intake amounts varied based on volume 
consumed, but the fish and borage oil group received up to an estimated 26mg per day of GLA. 
This is the equivalent of between 3 and 17 mg/kg/day depending o n the ch ild’s body composition 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 25 
 and age.  Although Fewtrell and colleagues35 stated adverse events were present in both formula 
groups, the fish and borage oil group experienced more days on ventilator, more days on o xygen, 
and more days with umbilical catheter. Although these adverse events were reported, many pre -
existed randomization.  The infants in that study were already NICU patients with multiple co -
morbidities present before randomization. Because of the older  age of the participants in this study, 
adverse events such as those reported by Fewtrell and colleagues are not anticipated .35 
The placebo for this study will be canola oil with a natural lemon oil flavoring added.   Canola oil is a 
commonly consumed food present in many prepared food products.  Whether it is possible to have 
an allergy to canola/rapeseed is controversial, but very rarely some people may have a non -allergic 
reaction.  Nevertheless, we will exclude any  children whose parent states they have 
canola/rapeseed allergy or sensitivity.  Lemon oil is Generally Recognized as Safe (GRAS) by the 
FDA.  
 
The study staff will maintain confidentiality of the data in its databases. Data will be summarized in 
aggregate for reporting purposes. Data submitted to the study does include participant identifiers, 
as defined by the U.S. Health Insurance Portability and Accountability Act of 1996 (HIPAA).  The 
study will follow all necessary measures to assure the participant da ta stored in the database are 
protected and secure from unauthorized access.   
The knowledge to be gained from this investigation outweighs these minimal risks. This study has  
the potential to inform future dietary recommendations for  children , especially those diagnosed with 
ASD and  associated comorbidities . 
9.2 Benefits  
Omega fatty acid  supplementation may benefit participating children by reducing their ASD 
symptomology, and comorbidities . It is not known if these benefits exist. Participation in this study 
will aid in acquiring new knowledge that might help other children with an ASD diagnosis and their 
families in the future.  
 
There are no other known benefits expected from participation in this study.  
  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 26 
 10  ASSESSMENT OF SAFETY  
10.1 Methods and Timing for Assess ing, Recording, and Analyzing Safety Parameters  
Safety oversight will be under the direction of the Principal Investigator s (PIs), Study Doctor, and 
the Independent Study Safety Monitor. All adverse events will be reviewed to rule out the study 
interventio n as a potential cause. All Adverse  Events  will be recorded  on a form designated  for 
that purpose,  labeled  with a participant  ID and no personal  identifiers.  For any adverse  events  
required  to be reported  to the IRB or the FDA,  and for review  purposes  by the Independent  
Monitoring  Committee  (IMC),  only the coded  ID number  will be included  in the documentation  as 
needed,  and no identifiers.  The IMC will review  adverse  events  anonymously.  If the child’s  
medical  record  must  be accessed  to provide  additional  details as to the event  or its treatment,  
study  staff will provide abstracted information  that is  de-identified.  Annual reports of findings will be 
submitted to the FDA in line with IND regulations.  
   
10.2 Adverse Events  
Adverse Event  (AE):  ICH E6 defines an AE  as any untoward medical occurrence in a patient or 
clinical investigation  participant  administered a pharmaceutical product regardless of its causal 
relationship to the study treatment. An AE can therefore be any unfavorable and unintended sign 
(including  an abnormal laboratory finding), symptom, or disease temporally associ ated with the use 
of investigational  product. The occurrence of an AE may come to the attention of study personnel 
during study visits and interviews of a study recipient presenting for  medical care, or upon review by 
a study monitor.  
All AEs including local and systemic reactions not meeting the criteria for “serious adverse events” 
should be captured on the appropriate CRF. Information to be collected includes event description, 
time of onset, Study Doctor ’s assessment of severity, relationship to study product (assessed only 
by those with the training and authority to make a diagnosis, which would include MD, PA, Nurse 
Practitioner, DO, or DDS), and time of resolution/stabilization of  the event. All AEs occurring during  
study  participation  must be documented appropriately regardless of relationship. All AEs will be 
followed to adequate resolution.  
Any medical condition that is present at the time that the participant is screened shoul d be 
considered as baseline and not reported as an AE. However, if  the medical condition  deteriorates at 
any time during the study, it should be recorded as an AE.  
All AEs must be graded for severity and relationship to study product.  
Severity of Event:   All AEs will be assessed by the Study Doctor  using a protocol defined grading 
system. For events not included in the pr otocol defined grading system, the following guidelines will 
be used to quantify intensity.  
 Mild: events require minimal or no treatment  and do not interfere with the participant’s daily 
activities.  
 Moderate : events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
 Severe : events interrupt a partic ipant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually incapacitating.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 27 
  Life threatening :  any adverse drug experience that places the participant , in the view of the  PI, 
at immediate risk of death f rom the reaction as it occurred  (i.e., it does not include a reaction 
that had it occurred in a more severe form, might have caused death ). 
Changes in the severity of an AE should be documented to allow an assessment of the duration of 
the event at each le vel of intensity to be performed. Adverse events characterized as intermittent 
require documentation of onset and duration of each episode.  
Relationship to Study Products:   The Study Doctor ’s assessment of an AE's relationship to study 
intervention is part  of the documentation process, but it is not a factor in determining what is or is 
not reported in the study. If there is any doubt as to whether a clinical observation is an AE, the 
event should be reported. All AEs must have their relationship to study p roduct assessed using the 
terms: related or  not related . In a clinical trial, the study product must always be suspect. To help 
assess, the following guidelines are used.  
 Related  (Possible, Probable, Definite)  
a. The event is known to occur with the study int ervention.  
b. There is a temporal relationship between the intervention and event onset.  
c.    The event abates when the intervention is discontinued.  
d. The event reappears upon a re -challenge with the intervention.  
 Not Related  (Unlikely, Not Related)  
a. There is no temporal relationship between the intervention and event onset.  
b. An alternate etiology has been established.  
 
10.3 Unanticipated Problems  
The Office for Human Research Protections (OHRP) considers unanticipated problems 
involving risks to subjects or others to i nclude, in general, any incident, experience, or outcome 
that meets all of the following criteria:  
 Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved 
research protocol and informed consent document; and (b) the characteristics of the 
subject population being studied;  
 Related or possibly related to participation in the research (“possibly related” means 
there is a reasonable possibility that th e incident, experience, or outcome may have 
been caused by the procedures involved in the research); and  
 Suggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was p reviously known or 
recognized.  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 28 
 10.3.1  Reporting Unanticipated Problems  
Incidents or events that meet the OHRP criteria for unanticipated problems will be reported 
using an unanticipated problem report form.  The unanticipated problem report form will include 
the following information when reporting an adverse event, or any other incident, experience, or 
outcome as an unanticipated problem to the IRB:  
 Appropriate identifying information for the research protocol, such as the title, 
investigator’s name, and the IRB  project number;  
 A detailed description of the adverse event, incident, experience, or outcome;  
 An explanation of the basis for determining that the adverse event, incident, experience, 
or outcome represents an unanticipated problem;  
 A description of any  changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the unanticipated problem.  
To satisfy the requirement for prompt reporting, unanticipated problems will be reported using 
the following timeline:   
 Unanticipated problems that are serious adverse events will be reported to the IRB, 
Independent Safety Monitor(s), and NCCIH within 7 days of the investigator becoming 
aware of the event.  
 Any other unanticipated problem will be reported to the IRB, Independe nt Safety 
Monitor(s), and NCCIH within 14 days of the investigator becoming aware of the 
problem.  
All unanticipated problems should be reported to appropriate institutional officials (as required 
by an institution’s written reporting procedures), the supp orting agency head (or designee), and 
OHRP within one month of the IRB’s receipt of the report of the problem from the investigator.  
10.4 Serious Adverse Events  
Serious Adverse Event (SAE) : An SAE is defined as an AE that meets one of the following 
conditions:  
 
 Death during the period of protocol defined surveillance . 
 Life-threatening event (defined as a subject at immediate risk of death at the time of the 
event) . 
 An event requiring inpatient hospitalization or prolongation of existing hospitalization during 
the period o f protocol defined surveillance.  
 Results in congenital anomaly or birth defect . 
 Results in a persistent or significant disability/incapacity . 
 Any other important medical event that may not result in death, be life threatening, or 
require hospital ization, may be considered a serious adverse experience when, based upon 
appropriate medical judgment, the event may jeopardize the subject and may require 
medical or surgical intervention to prevent one of the outcomes listed above. Examples of 
such medic al events include allergic bronchospasm requiring intensive treatment in an 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 29 
 emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse.  
The Study PI and In dependent Monitoring Committee will be responsible for determining 
whether an SAE is expected or unexpected.  An adverse event will be considered unexpected if 
the nature, severity, or frequency of the event is not consistent with the risk information 
previously described for the intervention.   
 
All SAEs will be:  
 Recorded on the appropriate SAE CRF . 
 Followed through  resolution by a Study Doctor . 
 Reviewed an d evaluated by a Study Doctor . 
10.4.1  Reporting  SAE’s  
Any AE considered serious by the PI or Study Doctor or  which meets the aforementioned criteria 
must be submitted on an SAE form to the NCH IRB within 3 business days of discovery.  All SAEs 
will be followed until satisfactory resolution or until the Study Doctor deems the event to be chronic 
or the patient to  be stable.  
 
Annual reports of findings will be submitted to the FDA in line with IND regulations.  
 
SAEs that are unanticipated, serious, and possibly related to the study intervention will be 
reported to the Independent Monitors(s), IRB, FDA, and NCCIH i n accordance with 
requirements.  For the IND:  
 7-day IND Safety Report (unexpected fatal or life -threatening AEs related to the 
intervention); a copy of the report sent to the FDA will be submitted to the NCCIH 
Program Officer and Independent Safety Monito r(s) within 24 hours of FDA notification.  
 15-day IND Safety Report (any other serious and unexpected AE related to the 
intervention); a copy of the report submitted to the FDA will be submitted to the NCCIH 
Program Officer and Independent Safety Monitor(s ) within 24 hours of FDA notification.  
 All other AEs documented during the course of the trial will be reported to NCCIH on an 
annual basis by way of inclusion in the annual report and in the annual AE summary 
which will be provided to NCCIH and to the In dependent Monitors.  The Independent 
Safety Monitor(s) Report will state that all AEs have been reviewed.  
10.5 Procedures in the Event of Abnormal Laboratory Test Values/ Clinical Findings  
Collection of laboratory data should be limited to those laboratory param eters that are relevant to 
safety, study outcome measures, and/or clinical outcome. No known fatty acid value is considered 
to be abnormal or to present a safety concern.  As a result, it is not anticipated that any abnormal 
laboratory values will be found . However, a ny abnormal clinical findings will be reported to the 
child’s physicians.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 30 
 10.6 Type and Duration of Follow -up of Subjects after Adverse Events  
Unanticipated problems  will be recorded in the data collection system throughout the study.  
The PI will r ecord all reportable events with start dates occurring any time after informed consent is 
obtained until 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study participation. 
At each study visit, the investigator will inquire about the o ccurrence of AE/SAEs since the last visit. 
Events will be followed for outcome information until resolution or stabilization.  
10.7  Halting Rules  
If it is found that the study intervention  is related to any serious adverse events, enrollment would 
be tem poraril y suspend ed until a safety review is co nvened , the objective of which is a decision as 
to whether the study (or intervention for an individual or study cohort) should continue per protocol, 
proceed with caution, be further investigated, be discontinued, or  be modified and then proceed. 
Suspension of enrollment (for a particular group or for the entire study) is another potential outcome 
of a safety review.  
 
Subsequent review of serious, unexpected, and related AEs by the PI, Study Doctor, the 
Independent St udy Safety Monitor, the IRB , or the FDA or relevant local regulatory authorities may 
also result in suspension of further trial interventions/administration of study product . The FDA  
retain s the authority to suspend additional enrollment and study interven tions/administration of 
study product for the entire study, as applicable.  
 
Based on the large number of previous studies that have utilized a similar intervention in children 
and the widespread use of the study products in the U.S. consumer marketplace, t here are no 
expectations for halting the study enrollment or intervention due to safety concerns.  However, it will 
be left to the judgment of the PI with the advice of the Study Doctor and Safety Monitor whether a 
pattern of adverse events or other circum stances warrant halting.   
10.8 Safety Oversight  
Safety oversight will be under the direction of the PIs and Independent Study Safety Monitor . All 
adverse events will be reviewed to rule out the study intervention as a potential cause.   
 
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 31 
 11 STATISTICAL CONSIDER ATIONS  
11.1 Study hypotheses  
This study will test the hypothesis that Omega 3 -6 will produce a clinically significant reduction 
(improvement) in plasma levels of IL -1β, IL -2, and/or IFN  and assess bioavailability  and safety, 
of this product.  
11.2 Sample Size Conside rations  
Our power analysis is based on a comparison on pre -post change between all the placebo 
group participants compared to all treatment group participants receiving any Omega 3 -6. We 
use a Type I error rate of .05 to test our primary aim that at least one of our inflammatory 
markers will demonstrate improvements from baseline to posttest compared to the placebo 
group.  
  
For the purposes of examining power, we assume an independent sa mples t -test on pre -post 
change with ≥80% power to obtain a sufficient per group sample size (n), equal across groups. 
Consequently, the standardized mean difference ) is the effect size of interest. We base our 
estimate of the intervention effect size o n our Preemie Tot s study where s of .75, .77, and 1.04 
were obtained for the inflammatory markers of IL -1, IL-2, and IFN  respectively. We propose 
as part of our go/no -go decision for proceeding to the next phase of research (a second trial). 
This effect size (effect on inflammation) is clinically meaningful, based on the meta -analysis by Masi 
which compared children with ASD to typically -developing children and observed differences in 
cytokine levels of and 1.0 for 2 of our biomarkers of int erest.41 Importantly, the dose used in 
Preemie Tots is comparable to the smallest dose treatment group here; consequently, if a dose 
effect does indeed exist across the treatment groups,  we expect  the effect sizes we observe will be 
even larger in the pres ent study when compared to the placebo group. Given these effect sizes and 
conservatively accounting for attrition rates of 10%, n=33 for each of the placebo and treatment 
groups will allow us to detect treatment effects with at least 80% power.36  
 
11.3 Planned Interim Analyses (if applicable)  
No interim analysis is planned.  
 
11.3.1  Safety Review  
Based on th e large number of previous studies that have utilized the same intervention in similar 
populations and the widespread use of the study products in the U.S. consumer marketplace, 
there are no expectations for halting the study enrollment or intervention due  to safety concerns. 
 However, it will be left to the judgment of the Principal Investigator with the advice of the IMC 
whether a pattern of adverse events or other circumstances warrant halting.  See the section 
“Assessment of Safety” for details about sa fety monitoring.  
 
11.3.2  Immunogenicity or Efficacy Review  
None  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 32 
 11.4 Final Analysis Plan  
 
Aim 1  
Aim 1 Primary Analysis:  To examine group differences in bioavailability and safety, we will 
compare the entire treatment group to the entire placebo group, and at the diff erent dosing 
levels within treatment, by: 1) comparing mean and median %FA for each fatty acid at the end 
of the trial and 2) comparing the total number of adverse events that occurred in each group and 
also by adverse event type (e.g., gastrointestinal; s evere vs . not).  
 
Aim 1 Secondary analysis : Demonstrate th at children receiving Omega 3 -6 will exhibit a 
clinically relevant absolute increase in RBC EPA or DHA of at least 0.5 mol%, between baseline 
and the end of the trial (i.e., an increase of approx. 2 0% for DHA, 67% for EPA depending on 
baseline status).  
 
Aim 1 Secondary analysis (exploratory):  Explore the effect of dose on changes in RBC EPA and 
DHA by examining differences in the increase in RBC EPA and DHA by assigned dose among 
children assigned to  Omega 3 -6. 
 
 
Aim 2  
Aim 2 Primary Analysis:  To formally examine the efficacy of the intervention, the primary 
analysis will be to compare the treatment group, where anyone assigned to Omega 3 -6 is 
considered a member, to the placebo group where anyone ass igned to placebo is a member, on 
pre-post change in each inflammatory marker.  
 
Aim 2 Secondary analysis  (exploratory) : Explore  the effect  of dose  by 
comparing  each  Omega  3-6 dose  to the placebo group  (all children  assigned  to 
placebo)  on pre -post change  in each  inflammatory  marker.  
 
 
The primary approach for the analyses is intent -to-treat: individuals will be kept in the group to 
which they were randomized, regardless of protocol violations or drop -out. Every effort will be made 
to minimize missing data. A nalyses will explore plausible missing data mechanisms, and baseline 
predictors of missingness will be investigated. Also, when possible maximum likelihood estimation 
(MLE) will be employed where predictor variables associated with missingness will be inve stigated 
in sensitivity analyses. MLE generally provides valid inferences when the missing data mechanism 
is missing at random37 and is more appropriate than many commonly employed approaches to data 
imputation.38 
 
We will examine group differences d escriptively on bioavailability and safety data for the entire 
placebo group, the entire treatment group, and (secondarily, exploratory) at the different dosing 
levels within treatment. Specifically, for the Primary Analysis in Aim 1, we will use the indep endent 
samples t -test and the Wilcoxon rank -sum test to examine treatment vs. placebo group differences 
on the %FA for each fatty acid at the end of the trial, the total number of adverse events, and 
number adverse events by event type. This approach will allow us to examine both parametric and 
non-parametric approaches to group differences on each of these measures of bioavailability or 
safety.  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 33 
 For the Secondary Analysis in Aim 1, we will calculate the increase for each of RBC EPA and DHA 
to determine if  a clinically relevant value is obtained. For the Exploratory component of our 
Secondary Analysis in Aim 1, we will employ a repeated -measures mixed effects model to examine 
change in each of RBC EPA and DHA as a function of dose within the treatment group  only.  
 
For the Primary Analysis in Aim 2 to formally examine the efficacy of the intervention we will 
compare the treatment group where anyone given Omega 3 -6 is considered a member to the 
placebo group when anyone given a placebo dose is considered a member on  pre-post change in 
each inflammatory marker. The following is an illustration of our statistical model for repeated 
measures (RM), similar to analysis of covariance (ANCOVA) but based on maximum likelihood  
estimation, that will be employed for the se analyses39: 
it i t t it Trt Time Time y   2 1 0  , where 
implicitly it is assumed that there is no main effect of 
iTrt , 
ity is the value for a given inflammatory 
marker for individual i at time t, 
t Time   is coded as 0 for the pretest and 1 for the 90 -day post -
treatment, and the primary effect of interest is 
2 , which corresponds to the difference between the 
groups on change in the inflammatory marker of interest. In this RM model, the baseline measure of 
the individual’s inflammatory  marker is constrained to have equal means across groups by 
assuming there is no main effect for 
iTrt . This constraint yields a statistical test for 
2 analogous to 
the test of the treatment group main effect in an ANCO VA covarying the pretest measure of the 
outcome variable. The main advantage of the RM model is that it can be estimated in SAS PROC 
MIXED using maximum likelihood estimation on all available data by treating 
t Time  as a repeated 
measures f actor with 2 levels, whereas an ANCOVA model would require listwise deletion for 
missing data.38  
 
Importantly, for the Secondary/Exploratory Analysis in Aim 2, we will investigate the dose effect by 
using dosage given to a participant as quantitative and categorical predictors within separate 
models in place of the treatment effect variable, 
iTrt , using the same type of model used in the 
previous analysis. Because of the ex ploratory nature of our hypotheses concerning the parametric 
form of the relationship between dose and the response in each inflammatory marker, separate 
analyses using quantitative and categorical versions of the dosing variable will allow us to fully 
explicate the dose -response relationship. We will conduct exploratory analyses by child sex to 
examine sex as a modifier.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 34 
 12 SOURCE DOCUMENTS AND  ACCESS TO SOURCE DA TA/DOCUMENTS  
The study  will maintain appropriate medical and research records for this trial, in compliance with 
ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality 
of subjects. Only authorized Study S taff and NCH IRB staff will have access to the documents.   
Source data are all information, origina l records of clinical findings, observations, or other activities 
in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples of these 
original documents and data records include, but are not limited to, caregiver completed 
questionnaires/interviews, hospital records, clinical and office charts, laboratory notes, memoranda, 
subjects’ memory aid or evaluation checklists, pharmacy dispensing records, recorded data from 
automated instruments, copies or transcriptions certified af ter verification as being accurate and 
complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, and subject 
files and records kept at the pharmacy, at the laboratories, and medico -technical departments 
involved in the clinical tr ial. It is acceptable to use CRFs as source documents.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 35 
 13 QUALITY CONTROL AND QUALITY ASSURANCE  
The quality management program for this study will consist of a system of quality checks on all data 
collection procedures in addition to a system of training.   
All study staff that will have contact with study participants will be trained in accordance with the 
gold standard f or each data collection method.  At periodic intervals the quality of the data 
collections being performed will be evaluated  by direct obser vations by the PI or a designated 
subject matter expert.  All paper -based data collection will be evaluated for protocol compliance, 
completeness, and accuracy by the PI via direct observation of Study Staff and checks of the 
completed forms.  Data entry q uality will be assessed by a random check of 10% of the data 
entries.  Laboratory quality control and assurance procedures will follow SO P already in place in the 
laboratory and used  during previous studies.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 36 
 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.1 Ethical Stan dard  
The investigator will ensure that this study is conducted in full conformity with the principles set forth 
in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research of the US National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal 
Regulations 25691 (1997).   
14.2 Institutional Review Board  (IRB)  
The Nationwide Children’s Hospital IRB will review  and approve the protocol for this study including 
the associated informed consent documents and recruitment material s. Any amendments to the 
protocol or consent materials  will also be approved before they are placed into use.  
14.3 Informed Consent  
Informed c onsent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continuing throughout the individual’s study participation. D iscussion of risks and possible 
benefits will be conducted with  the participants  and their  families. Consent forms describing , in 
detail , the study interventions/products, study procedures, and risks are given to the family  and 
written documentation of informed consent is required prior to starting intervention/administering 
study product. Cons ent forms will be IRB -approved and the parent  will be asked to read and review 
the document. Upon reviewing the document, Study Staff will explain the research study and 
answer any questions that may arise. The parent will sign the informed consent documen t prior to  
randomization and  any procedures being done specifically for the study. The parent  will have the 
opportunity to discuss the study with his/her  family  or think about it prior to agreeing to participate. 
The participant  may withdraw consent at any  time. A copy of the informed consent docume nt will be 
given to the family  for their records. The rights and welfare of the participants will be protected by 
emphasizing to them that the quality of their medical care will not be adversely affected if they 
decline to participate in this study.  
14.3.1  Informed Consent/Assent Process (in Case of a Minor)  
Children may participate in this study under the written informed consent provided by a parent or 
legal guardian.   
 
Children of a parent who is cognitively impaired  or mentally ill are not eligible if the parent is not 
able to understand fully the research project and to grant informed consent.  
14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
The stu dy will not exclude any special populations.  
14.5 Subj ect Confidentiality  
Subject confidentiality is strictly held in trust by the participating investigators, their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples 
and genetic tests in additio n to the clinical information relating to participating subjects.  
The study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauth orized 
third party.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 37 
 An Independent Study Safety Monitor  or other authorized representatives may inspect all 
documents and records required to be maintained, including but not limited to, data collection 
records  and pharmacy records for the subjects in this  study. Records will be retained indefinitely.  
14.6 Study Discontinuation  
In the event that the study is discontinued, participants may discontinue use of the treatment oil  and 
placebo oil safely.  There is no known risk to discontinuation.  
14.7 Future Use of Store d Specimens  
Any r esidual specimens will be maintained after the study is complete  and will be available for 
future analysis and use, per the participant  informed  consent document.  Specimens may be 
analyzed for future studies of child nutrition, neurodevel opment and behavior and growth.   
Specimens will be maintained  in a secure location in the Center for Perinatal Research or Center for 
Biobehavioral Health  at NCH  and will be labeled with a numeric code a nd no identifying information. 
This is noted on the consent form and additional consent to bank leftover biospecimens in this 
manner will be obtained from participating families. Only the investigators for this study will have 
access to these specimens and permission for future use.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 38 
 15 DATA HANDLING AND RE CORD  KEEPING  
The PI is responsible to ensure the accuracy, completeness, legibility, and timeliness of the data 
reported. All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data . Dark  ink is required to ensu re clarity of reproduced copies. When making 
changes or corrections, cross out the original entry with a single line, and initial and date the 
change.  
Copies of the CRF will be  used as source documents and maintained for recording data for each  
participan t enrolled in t he study. Data reported in the CRF derived from source documents should 
be consistent with the source documents or the discrepancies should be explained . 
15.1 Data Management Responsibilities  
All source documents and laboratory reports will be re viewed by the investigator team  and data 
entry staff, who will ensure that they are accurate and complete. Adverse events must be graded, 
assessed for severity and cau sality, and reviewed by the  PI or designee.  
 
Data collection is the responsibility of the  Study Staff under the supervision of the PI. During the 
study, the investigator must maintain complete and accurate documentation for the study.  
 
The Study Staff is  also responsible for  data management, quality review, analysis, and reporting of 
the study  data under the direction of the investigator team.  
15.2 Data Capture Methods  
For the purposes of this pilot study, data capture will be via paper  and electronic methods (e.g., Red 
Cap) .  The data entry system will include password protection and internal quali ty checks, such as 
automatic range checks  and data validation , to identify data that appear inconsistent, incomplete, or 
inaccurate. Clinical data will be entered directly from the source documents.  
15.3 Types of Data  
Data for this study will include questionn aires, interviews , medical record , and laboratory  measures . 
15.4 Study Records Retention  
Study records will be kept in a secure, locked location in the Center for Biobehavioral Health at 
NCH and kept per procedures laid out in federal regulations.  
15.5 Protocol Devi ations  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice 
(GCP), or Manual of Procedures requirements. The noncompliance may be either on the part of the 
subject, the  investigator, or the Study Staff . As a re sult of deviations, corrective actions are to be 
implemented promptly.  
 
These practices are consistent with ICH E6:  
 
4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
5.1 Quality Assurance and Quality Control, section 5.1.1  
5.20 Noncompliance , sections 5.20.1, and 5.20.2.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 39 
 All deviations from the protocol must be addressed in  study subject source documents and  must be 
maintained in the regulatory file, as well as in the subject’s source document. Protocol deviations 
must be sent to the local IR B per their guidelines.  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 40 
 16 PUBLICATION POLICY  
Following completion of the study, the PI is expected to publish the results of this research in 
scientific journal s. The International Committee of Medical Journal Editors (ICMJE) member journals 
have adopted a  trials -registration policy as a condition for publication. This policy requires that all 
clinical trials be registered in a public trials registry such as ClinicalTrials.gov , which is sponsored by 
the Nationa l Library of Medicine. Other biomedical journals are considering adopting similar 
policies.  The PI will register this trial in an acceptable registry.  
 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 41 
 17 LITERATURE REFERENCE S 
 
1. Bent S, Bertoglio K, Ashwood P, Bostrom A, Hendren RL. A pilot randomized 
controlled trial of omega -3 fatty acids for autism spectrum disorder. J Autism Dev 
Disord. 2011;41(5):545 -554. 
2. Bent S, Hendren RL, Zandi T, et al. Internet -based, randomized, controlled trial of 
omega -3 fatty acids for hyperactivity in autism. J Am Acad Child Adolesc Psychiatry. 
2014;53(6):658 -666. 
3. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega -3 
fatty acids supplementation in children with autism: a double -blind randomized, 
placebo -controlled pilot study. Biol Psychiatry. 2007;61(4):551 -553. 
4. Martinez M. Polyunsaturated fatty acids in the developing human brain, red cells 
and plasma: influence of nutrition and peroxisomal disease. World Rev Nutr Diet. 
1994;75:70 -78. 
5. McPheeters ML, Warren Z, Sathe N, et  al. A systematic review of medical 
treatments for children with autism spectrum disorders. Pediatrics. 
2011;127(5):e1312 -1321.  
6. Chalon S. Omega -3 fatty acids and monoamine neurotransmission. Prostaglandins 
Leukot Essent Fatty Acids. 2006;75(4 -5):259 -269. 
7. Bazan NG. Cell survival matters: docosahexaenoic acid signaling, neuroprotection 
and photoreceptors. Trends in neurosciences. 2006;29(5):263 -271. 
8. Kitajka K, Puskas LG, Zvara A, et al. The role of n -3 polyunsaturated fatty acids in 
brain: modulation  of rat brain gene expression by dietary n -3 fatty acids. Proc Natl 
Acad Sci U S A. 2002;99(5):2619 -2624.  
9. Coti Bertrand P, O'Kusky JR, Innis SM. Maternal dietary (n -3) fatty acid deficiency 
alters neurogenesis in the embryonic rat brain. J Nutr. 2006;13 6(6):1570 -1575.  
10. Salem N, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic 
acid in the nervous system. Lipids. 2001;36(9):945 -959. 
11. Simopoulos AP. Omega -3 fatty acids in inflammation and autoimmune diseases. J 
Am Coll Nutr. 2002; 21(6):495 -505. 
12. Sergeant S, Rahbar E, Chilton FH. Gamma -linolenic acid, Dihommo -gamma 
linolenic, Eicosanoids and Inflammatory Processes. European journal of 
pharmacology. 2016;785:77 -86. 
13. Brigandi SA, Shao H, Qian SY, Shen YP, Wu BL, Kang JX. Autisti c Children Exhibit 
Decreased Levels of Essential Fatty Acids in Red Blood Cells. International journal 
of molecular sciences. 2015;16(5):10061 -10076.  
14. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic 
children. Prostagland ins Leukot Essent Fatty Acids. 2001;65(1):1 -7. 
15. Innis SM. Dietary omega 3 fatty acids and the developing brain. Brain research. 
2008;1237:35 -43. 
16. Makrides M, Gibson RA, McPhee AJ, et al. Neurodevelopmental outcomes of 
preterm infants fed high -dose do cosahexaenoic acid: a randomized controlled trial. 
JAMA. 2009;301(2):175 -182. 
17. Johnson CR, Handen BL, Zimmer M, Sacco K. Polyunsaturated Fatty Acid 
Supplementation in Young Children with Autism. JOURNAL OF DEVELOPMENTAL 
AND PHYSICAL DISABILITIES. 2010;2 2(1):1 -10. 
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 42 
 18. Abdallah MW, Larsen N, Grove J, et al. Amniotic fluid chemokines and autism 
spectrum disorders: an exploratory study utilizing a Danish Historic Birth Cohort. 
Brain, behavior, and immunity. 2012;26(1):170 -176. 
19. Mankad D, Dupuis A, Smile S , et al. A randomized, placebo controlled trial of 
omega -3 fatty acids in the treatment of young children with autism. Mol Autism. 
2015;6:18.  
20. Bloch MH, Qawasmi A. Omega -3 fatty acid supplementation for the treatment of 
children with attention -deficit/h yperactivity disorder symptomatology: systematic 
review and meta -analysis. J Am Acad Child Adolesc Psychiatry. 2011;50(10):991 -
1000.  
21. Puri BK, Martins JG. Which polyunsaturated fatty acids are active in children with 
attention -deficit hyperactivity diso rder receiving PUFA supplementation? A fatty acid 
validated meta -regression analysis of randomized controlled trials. Prostaglandins 
Leukot Essent Fatty Acids. 2014;90(5):179 -189. 
22. Richardson AJ, Montgomery P. The Oxford -Durham study: a randomized, cont rolled 
trial of dietary supplementation with fatty acids in children with developmental 
coordination disorder. Pediatrics. 2005;115(5):1360 -1366.  
23. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and 
micronutrients on learning  and behavior problems associated with child ADHD. 
Journal of developmental and behavioral pediatrics : JDBP. 2007;28(2):82 -91. 
24. Xu N, Li X, Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic 
dysfunction in autism spectrum disorders. Mediators of inflammation. 
2015;2015:531518.  
25. Anisman H, Hayley S, Turrin N, Merali Z. Cytokines as a stressor: implications for 
depressive illness. The international journal of neuropsychopharmacology. 
2002;5(4):357 -373. 
26. Vezzani A, Viviani B. Neurom odulatory properties of inflammatory cytokines and 
their impact on neuronal excitability. Neuropharmacology. 2015;96(Pt A):70 -82. 
27. Petitto JM, Meola D, Huang Z. Interleukin -2 and the brain: dissecting central versus 
peripheral contributions using unique  mouse models. Methods in molecular biology. 
2012;934:301 -311. 
28. Tostes MH, Teixeira HC, Gattaz WF, Brandao MA, Raposo NR. Altered 
neurotrophin, neuropeptide, cytokines and nitric oxide levels in autism. 
Pharmacopsychiatry. 2012;45(6):241 -243. 
29. Sweete n TL, Posey DJ, Shankar S, McDougle CJ. High nitric oxide production in 
autistic disorder: a possible role for interferon -gamma. Biol Psychiatry. 
2004;55(4):434 -437. 
30. Lazear HM, Nice TJ, Diamond MS. Interferon -lambda: Immune Functions at Barrier 
Surface s and Beyond. Immunity. 2015;43(1):15 -28. 
31. Masi A, Quintana DS, Glozier N, Lloyd AR, Hickie IB, Guastella AJ. Cytokine 
aberrations in autism spectrum disorder: a systematic review and meta -analysis. 
Molecular psychiatry. 2015;20(4):440 -446. 
32. Carlson SE, Cooke RJ, Rhodes PG, Peeples JM, Werkman SH. Effect of vegetable 
and marine oils in preterm infant formulas on blood arachidonic and 
docosahexaenoic acids. The Journal of Pediatrics. 1992;120(4, Part 2):S159 -S167.  
              Fatty acid supplements alter biological signat ures in ASD                                                                                       Updated:  
CONFIDENTIAL                                                                                                                                                                 22 May 2018  
 
 
 43 
 33. Horrobin DF. Nutritional and medic al importance of gamma -linolenic acid. Prog Lipid 
Res. 1992;31(2):163 -194. 
34. Vaddadi KS. The use of gamma -linolenic acid and linoleic acid to differentiate 
between temporal lobe epilepsy and schizophrenia. Prostaglandins Med. 
1981;6(4):375 -379. 
35. Fewtr ell MS, Abbott RA, Kennedy K, et al. Randomized, double -blind trial of long -
chain polyunsaturated fatty acid supplementation with fish oil and borage oil in 
preterm infants. J Pediatr. 2004;144(4):471 -479. 
36. Cohen J. Statistical power analysis for the be havioral sciences.  2nd ed. Hillsdale, 
NJ: Erlbaum; 1988.  
37. Rubin D. Inference and missing data. Biometrika. 1976;63:581 -592. 
38. Schafer JG, Graham JW. Missing data: Our view of the state of the art. 
Psychological methods. 2002;7(2):147 -177. 
39. Winkens B, van Breukelen GJ, Schouten HJ, Berger MP. Randomized clinical trials 
with a pre - and a post -treatment measurement: repeated measures versus 
ANCOVA models. Contemporary clinical trials. 2007;28(6):713 -719. 
 
 
 
 
 